Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | REN | P00797 | 3/20 | 0.47 |
| ▸ | NAAA | Q02083 | 2/20 | 0.44 |
| ▸ | MMP8 | P22894 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.40 |
| ▸ | KDM4A | O75164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4040963 | 1.00 | REN (0.47) | RENNAAAMMP8HPGDLMNA | |
| SCHEMBL4047233 | 0.90 | CHRND (0.44) | CHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL5730463 | 0.90 | REN (0.41) | RENNAAA | |
| SCHEMBL4038910 | 0.88 | CHRND (0.48) | REN | |
| SCHEMBL4037775 | 0.86 | REN (0.49) | REN | |
| SCHEMBL4043492 | 0.85 | VNN1 (0.39) | RENMMP8 | |
| SCHEMBL4039170 | 0.85 | HPGD (0.41) | MMP8HPGDLMNAALDH1A1 | |
| SCHEMBL4044987 | 0.84 | MMP8 (0.51) | MMP8KMT2AALDH1A1 | |
| SCHEMBL4041195 | 0.82 | MMP1 (0.41) | RENMMP8 | |
| SCHEMBL4039656 | 0.79 | HDAC1 (0.42) | LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612054-B2 | Dibenzo[b,f]oxepine-10-carboxamides and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2009-11-03 | — | — | US | disclosed |
| WO-2009013293-A1 | SUBSTITUTED CYCLOHEXANECARBOXAMIDES USEFUL AS BACE INHIBITORS | NOVARTIS AG (CH) | 2009-01-29 | — | — | WO | disclosed |
| US-20070111991-A1 | Novel dibenzo [b, f] oxepine-10-carboxamides and pharmaceutical uses thereof | NOVARTIS AG (CH) | 2007-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070111991-A1 | Novel dibenzo [b, f] oxepine-10-carboxamides and pharmaceutical uses thereof | APP, BACE1, BCHE | REN 717/4885NAAA 477/4885MMP8 4741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.